Abstract:Background: Acute Myeloid Leukemia (AML) is a heterogeneous hematological malignancy with variable clinical outcomes. Identifying patient subsets with relevant prognostic outcomes and understanding their molecular characteristics is crucial for developing targeted therapies. This study aimed to characterize molecular subtypes in AML patients using unsupervised clustering analysis, and investigate the relationship between transcriptomic features, signaling/immune pathways, recurrent DNA variants, and prognostic potential. Here, we show the potential of applying an integrative multi-omics approach to define the disease biology of a unique poor prognostic subtype of AML to uncover potential targeted therapeutic strategies. Methods: An unsupervised dimensionality reducing approach (non-negative matrix factorization) followed by consensus clustering was performed on the Beat-AML (discovery dataset, N=462) and TCGA-AML (validation dataset, N=173) RNAseq data from patient samples to identify transcriptomic-based molecular subtypes. The top 1000 most variable genes were used to reduce noise. The biological significance of gene expression in the identified subtypes was analyzed using GSVA on Hallmark, KEGG and Reactome databases. Immune cell type abundance scores were calculated by xCell method. The presence of recurrent DNA variants was evaluated in each subtype. The association between subtypes and clinical outcome was tested using Kaplan Meier method and a log-rank test. The findings were then reproduced in the TCGA AML cohort. Results: Analysis in the Beat-AML cohort revealed 5 clusters, including cluster 3 (n=86; comprising 20% of the AML cases) which showed worse overall survival (OS) compared to the other subtypes (HR (95% CI) = 1.41 (1.03, 1.92, P=0.03). A co-mutation in the genes FLT3, NPM1 and DNMT3A was enriched in this subtype. Gene sets analysis showed enrichment of several pathways key to the mechanism of action of therapeutic antibodies, including enhanced enrichment of the complement pathway, NK cell-mediated cytotoxicity, and FCGR-mediated phagocytosis in this subgroup. Additionally, activation of oncogenic signaling (PI3K/AKT/MTOR, TGFβ, NOTCH), and metabolic pathways (fatty acid and oxidative phosphorylation) were enriched in this subgroup. Immune cell signatures showed elevated expression levels of M2 macrophages. The results were successfully reproduced in the TCGA AML cohort, validating the findings. Conclusion: This study identifies a distinct poor prognostic patient subpopulation in AML characterized by activation of immune and cancer related pathways, and enrichment of a specific co-mutation genotype. While co-mutation of NPM1/FLT3-ITD has been identified as an intermediate-risk genotype and DNMT3A mutation alone is associated with poor prognosis (Ley et al., 2010, N Engl J Med), the triple co-mutation enriched in cluster 3 of our analysis may itself lead to poor prognosis (Loghavi et al., 2014, J Hematol Oncol) but the biological features of this subtype have yet to be described. The transcriptome data revealed patients in cluster 3, which may include nearly 20% of AML, exhibited activation of oncogenic signaling pathways, metabolic stress, and an immunosuppressed tumor microenvironment - all characteristics of aggressive disease; there is also enrichment of genes driving NK cell-mediated cytotoxicity, FCGR-mediated phagocytosis, and complement cascade, highlighting a potential opportunity for antibody-based immune effector function-dependent interventions. Replication of the results in an independent cohort strengthens the robustness of the findings. This study enhances our understanding of AML heterogeneity and may have implications for developing targeted antibody-based strategies to treat high-risk subtypes, such as this specific molecular subgroup, ultimately improving patient outcomes in AML.

UMAP guided topological analysis of transcriptomic data for cancer subtyping

Robust correlation estimation and UMAP assisted topological analysis of omics data for disease subtyping

Robust clustering of noisy high-dimensional gene expression data for patients subtyping

Supervised Graph Clustering for Cancer Subtyping Based on Survival Analysis and Integration of Multi-Omic Tumor Data

Clustering of Transcriptomic Data for the Identification of Cancer Subtypes

Abstract 2497: Topological data analysis revealed complexity behind ER positive breast cancer subtypes in TCGA transcriptome data

Integrative Analysis of RNA Expression Data Unveils Distinct Cancer Types through Machine Learning Techniques

Outcome-Guided Disease Subtyping for High-Dimensional Omics Data

Automated Cancer Subtyping via Vector Quantization Mutual Information Maximization

Outcome-guided Bayesian clustering for disease subtype discovery using high-dimensional transcriptomic data

Learning vector quantized representation for cancer subtypes identification

Subtype-GAN: a deep learning approach for integrative cancer subtyping of multi-omics data

Integration of pan-cancer multi-omics data for novel mixed subgroup identification using machine learning methods

Subtype-Former: a deep learning approach for cancer subtype discovery with multi-omics data

Mining Heterogeneous Causal Effects for Personalized Cancer Treatment.

COPS: A novel platform for multi-omic disease subtype discovery via robust multi-objective evaluation of clustering algorithms

Unbiased Subtyping of AML: Unraveling Genomic and Transcriptomic Features for Precision Medicine and Targeted Therapies Using Beat-AML and TCGA Data

Cancer Subtyping via Embedded Unsupervised Learning on Transcriptomics Data

Cancer Subtyping by Improved Transcriptomic Features Using Vector Quantized Variational Autoencoder

Multi-Omics Data Fusion for Cancer Molecular Subtyping Using Sparse Canonical Correlation Analysis

Identifying cancer subtypes in glioblastoma by combining genomic, transcriptomic and epigenomic data